Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Barclays Downgrades Covetrus to Equal-Weight, Lowers Price Target to $21

Author: Benzinga Newsdesk | May 26, 2022 07:17am
Barclays analyst Balaji Prasad downgrades Covetrus (NASDAQ:CVET) from Overweight to Equal-Weight and lowers the price target from $26 to $21.

Posted In: CVET